Matchday Champions , a New Class of Mobile Football Game Now Available Worldwide; Kicks off With In-Game Event Hosted by Soccer Superstar Alexia Putellas and Mega Influencer Celine Dept
Matchday, the developer of innovative mobile games for football’s five billion fans, has debuted its newest title, Matchday Champions. Today, the game is in early access globally, and it is celebrating with the limited-time “Copa Alexia x Céline,” a one-of-a-kind in-game tournament hosted by Spanish football World Cup Champion Alexia Putellas, and the immensely popular Belgian influencer Celine Dept.
Backed by Lionel Messi’s Play Time fund, Alexia Putellas, and other industry legends in sports and games, Matchday Champions is a one-of-its-kind experience. The game allows players to collect, craft and manage their own dream squad made up of both men's and women's players. It delivers the excitement of football using a cutting edge narrative creation engine, ensuring no two matches are ever the same. More than two million people have already pre-registered ahead of launch. Matchday Champions is now available in early access globally for iOS and Android phones.
Players who download the game can sign up to participate in the Copa Alexia x Céline, beginning on September 20. Hosted by World Cup champion, two-time Ballon d’Or winner and UEFA Women's Player of the Year Alexia Putellas and influencer Celine Dept, a football mega-fan with more than 50 million followers on YouTube, TikTok and Instagram, Copa Alexia x Céline challenges players to join Team Alexia or Team Celine, squaring off in a virtual tournament for bragging rights and prizes.
“Matchday is elevating two things I am very passionate about: women’s football and inclusivity,” said Putellas. “Women’s football has been on the rise for the last decade and Matchday’s co-gender football squads represent this reality in a fun and novel way for fans. I am honored to be a part of and shape a (virtual) football world that gives men and women truly equal footing. I hope the sort of representation we see in Matchday’s games will inspire the women’s football stars and all football fans of tomorrow, and help to drive forward conversations around equality.”
Licensed by FIFA and FIFPRO, Matchday offers fans the ability to collect digital player cards from tens of thousands of soccer athletes, and to combine both men’s and women’s players into their ideal squad to go head-to-head with other players’ teams. Players begin by assembling their squad, which they can start upgrading immediately. They then send their starting 11 onto the pitch, and Matchday Champions' proprietary simulation engine renders exciting in-game narratives. Play against rivals and friends while earning resources and recruiting footballers to improve their squad. Matchday Champions authentically captures the euphoria and heartbreak of real life football, and every match unfolds in a unique way.
“Football is an emotional experience for its five billion fans worldwide, and now they will be able to experience the drama of the sport in a video game that can seamlessly simulate games based on real players, real stats, and more,” said Sebastien de Halleux, Matchday co-founder and chief gaming officer. “Few players have experienced the emotional highs of football like Alexia Putellas, winning a World Cup, three UEFA Women's Champion Leagues, and 21 domestic trophies, along with all of her incredible individual accolades, so we’re honored that she has joined us not only as a Matchday ambassador but as the host of our first global in-game tournament.”
In Matchday Champions, players build and strengthen their squad, competing against others to move up through divisions and grow their club, competing with friends and Matchday’s vibrant global community, already numbering in the millions. Custom squads can be set up with ease through Matchday Champions' intuitive and accessible interface, allowing players to experiment with their team formation, as well as buy, sell and share cards with friends. Players hone their team in single player mode, then step on the pitch for a friendly match or an epic league competition with fans from all over the world. They can also join fans on the official Discord in discussing everything football, participate in weekly contests, participate in AMAs with football celebrities and follow real-world football matches.
Matchday continues to push the boundaries of digital ownership with Matchday Champions, which is part of a new category of sports games wherein fans build virtual squads by collecting digital cards of their favorite footballers. Players have true ownership of their cards and other digital items within Matchday Champions as they collect, trade and grow their dream team. These officially licensed cards can be utilized in all games within the Matchday ecosystem as it continues to grow.
Matchday previously launched the trivia and match prediction game Matchday Challenge: FIFA Women’s World Cup AU∙NZ∙2023™ Edition, which ran during FIFA Women’s World Cup and was played by millions of players all over the world.
Players can download Matchday Champions for free on the App Store or Google Play.
To learn more, please visit matchday.com, and join Matchday on X and Discord for the latest updates.
About Matchday
Matchday builds games for 5 billion football fans featuring officially licensed players and tournaments, in partnership with FIFA and FIFPRO. The company was founded by technology and gaming veterans who have successfully started and sold companies including Playfish (acq. EA), Glu Mobile (IPO), Hoodline (acq. Nextdoor), Spin (acq. Ford), and Viki (acq. Rakuten). Matchday is incubated by Leo Messi’s Play Time and backed by leading investors, with teams in San Francisco and Barcelona.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240920697449/en/
Contacts
Sibel Sunar
fortyseven communications for Matchday
matchday@fortyseven.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PQE Group Joins Project-COMFORT to Advance Patient-Centric Blood Collection and Diagnostics30.12.2024 07:50:00 CET | Press Release
PQE Group, a global consulting firm specializing in Life Sciences, is proud to contribute its expertise as a strategic partner in the Project-COMFORT consortium. This innovative public-private partnership, funded by Horizon Europe and supported by the Innovative Health Initiative Joint Undertaking (IHI JU), officially launched in November 2024, marking a transformative shift in blood collection and diagnostics. The ambitious 42-month project brings together 51 organizations from a broad spectrum of sectors, including academia, research institutions, hospitals, foundations, SMEs, medical technology, and pharmaceutical companies, all united by the mission to simplify, reduce the invasiveness of, and increase accessibility to blood collection through cutting-edge, patient-centered microsampling technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241229266268/en/ Follow Project-Comfort LinkedIn Page: https://www.linkedin.
Medical-Fish-Skin Company Kerecis Expands Silicone Fish-Skin Combination Product Range for Surgical and Trauma Wound with SurgiClose® Silicone27.12.2024 20:00:00 CET | Press Release
Kerecis, the company pioneering the use of sustainably sourced fish skin and fatty acids in cellular therapy and tissue regeneration and protection, today announced the availability of SurgiClose® Silicone, which combines a fish-skin graft and silicone backing for efficient treatment of surgical and trauma wounds. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241227975454/en/ SurgiClose® Silicone (Photo: Business Wire) SurgiClose® Silicone is a part of the SurgiClose® product family, which is intact fish-skin intended for the management of trauma wounds and surgical wounds in the operating room. The new product is available in two variations, SurgiClose® Silicone Adhesive with borders that overlap the fish-skin underneath and SurgiClose® Silicone Standard with non-overlapping borders. “Applying Kerecis fish-skin to a surgical or trauma wound is a multi-step process that often requires supporting products such as sutures, st
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy27.12.2024 12:00:00 CET | Press Release
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr), in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1 (≥1). “Today’s FDA approval of TEVIMBRA for the treatment of gastric or gastroesophageal junction cancers in PD-L1 positive adult patients marks a significant step forward in our mission to deliver transformative therapies to patients with cancer,” said Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeiGene. “This is the second U.S. approval for TEVIMBRA this year, underscoring its potential to address critical needs in oncology. We remain deeply grateful to the patients, clinicians, and resear
Takeda Announces Approval of HYQVIA ® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia27.12.2024 07:00:00 CET | Press Release
Takeda (TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] in patients with agammaglobulinemia or hypogammaglobulinemia1, disorders characterized by very low or absent levels of antibodies and an increased risk of serious recurring infection caused by primary immunodeficiency (PID) or secondary immunodeficiency (SID)2. The approval marks availability of the first and only facilitated subcutaneous immunoglobulin (fSCIG) therapy as a treatment option for appropriate patients in Japan. HYQVIA is the first plasma-derived therapy for subcutaneous injection in Japan that consists of a combination of one vial of Immunoglobulin 10% and one vial of Recombinant Human Hyaluronidase PH20 (rHuPH20). The administration of rHuPH20 increases the dispersion and absorption of immunoglobulin (IG) in the subcutaneous tissue, allowing larger volumes to be infu
Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 15:00:00 CET | Press Release
Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 100 points. TIME and Statista analyzed 3,000 major companies from 150 countries, focusing exclusively on those with trans
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom